Journal Club

 

2020

Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report06.01.2020 (Sandra Zingg)
Peter Horby: Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report medRvix preprint https://doi.org/10.1101/2020.06.22.20137273 2020
Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial29.06.2020 (Sabine Kuster)
Deftereos S.G. et al: Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial JAMA Online June 2020, Vol 3, No. 6 1 -14 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial22.06.2020 (Mihaela Sava)
Zhu FC et al.: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial The Lancet 395 1845-54
2020 Mai
1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
15.06.2020 (Kai-Manuel Adam)
Diverse 3 Paper:
1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
medRxiv preprint Epub Epub 2020 Juni
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis08.06.2020 (Matthias von Rotz)
Mehra MR. et al.: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis The Lancet Nur online erschienen. 22. Mai 2020
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study25.05.2020 (Aurélien Emmanuel Martinez)
Verdoni L. et al.: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Lancet Online online 2020
Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure18.05.2020 (Ana Durovic)
Kucirka L.M. et al.: Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure ACP Journals doi.org/10.7326/M20-1495 2020
Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies11.05.2020 (Anne-Valérie Burgener)
Williams CM et al.: Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies Lancet Infect Dis. Volume 20 607-617
An analysis of SARS-CoV-2 viral load by patient age04.05.2020 (Silvio Ragozzino)
Terry CJ. et al: An analysis of SARS-CoV-2 viral load by patient age
Preprint – https://virologie-ccm.charite.de/
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial20.04.2020 (Sandra Zingg)
Mahévas M. et al: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial BMJ (medRxiv) 04/2020
Virological assessment of hospitalized patients with COVID-1906.04.2020 (Mihaela Sava)
Wölfel R et al.: Virological assessment of hospitalized patients with COVID-19
Nature 2020, published online April 1st , 2020
Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents30.03.2020 (Matthias von Rotz)
Kampf G. et al.: Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents Journal of Hospital Infection 104 246-251 2020
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study10.02.2020 (Sabine Kuster)
Nashan Chen et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet Infectious Disease Published Online January 29, 2020 1-7 2020
Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in
critically ill
06.01.2020 (Sandra Zingg)
Gloria Wong: Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in critically ill J Antimicrob Chemother 75 429-433 2020
Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial20.01.2020 (Elisabeth Wehrle)
Kaye K.: Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial CID 69 2045-2056 2019
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials13.01.2020 (Mihaela Sava)
Campbell R J. et al.: Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials Lancet Infect Dis 2019 Online First 2019